Pacira BioSciences, Inc. (PCRX) - Q3 2025 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended September 30, 2025. Pacira BioSciences, Inc. is a biopharmaceutical company focused on non-opioid pain therapies. Its core commercial products include EXPAREL (long-acting local analgesic), ZILRETTA (extended-release corticosteroid for knee OA), and iovera (cryoanalgesia device). The company is advancing PCRX-201, a gene therapy for knee OA, following the acquisition of GQ Bio Therapeutics GmbH in February 2025.
Key Financial Metrics
| Metric | Q3 2025 | Q3 2024 | YTD 9M 2025 | YTD 9M 2024 |
|---|---|---|---|---|
| Total Revenues | $179.5M | $168.6M | $529.5M | $513.7M |
| Net Product Sales | $178.0M | $167.7M | $526.0M | $509.9M |
| Net Income (Loss) | $5.4M | ($143.5M) | $5.4M | ($115.6M) |
| Diluted EPS | $0.12 | ($3.11) | $0.12 | ($2.50) |
| Gross Margin | 81% | 77% | 79% | 75% |
| Operating Cash Flow (9M) | $108.3M (2025) vs $156.3M (2024) | |||
| Cash & Investments (Sep 30, 2025) | $246.3M | |||
| Total Debt (Sep 30, 2025) | $376.7M |
Material Changes vs. Prior Period
- Profitability Turnaround: The company reported a net income of $5.4M in Q3 2025, a significant improvement from a net loss of $143.5M in Q3 2024. The prior year loss was heavily impacted by a $163.2M goodwill impairment charge.
- Revenue Growth: Total revenues increased 6% year-over-year in Q3 2025. EXPAREL sales grew 6% driven by a 9% increase in gross vial volume, while ZILRETTA sales grew 2%.
- Legal Settlements & Judgments:
- Inflow: Received a $23.1M cash judgment from the Research Development Foundation (RDF) regarding royalty disputes, recorded as other income.
- Outflow: Paid a $7.0M settlement to eVenus Pharmaceutical Laboratories regarding patent infringement litigation.
- Restructuring & Impairments: Recognized a $25.9M impairment of acquired in-process research and development (IPR&D) related to ZILRETTA shoulder indications. Incurred $3.7M in restructuring charges due to a reduction in force at the San Diego Science Center Campus to improve manufacturing efficiency.
- Debt Refinancing: Repaid the 2025 Convertible Senior Notes ($202.5M) and the Term Loan A facility ($98.8M). Entered a new $300M Revolving Credit Facility, with $96M outstanding as of period end.
Guidance, Outlook, and Risks
- Outlook: Management expects cash and investments to be sufficient to fund operations for the next 12 months. The company is advancing the Phase 2 ASCEND trial for PCRX-201, with interim analysis expected before the end of 2026.
- Strategic Initiatives:
- Entered a co-promotion agreement with Johnson & Johnson MedTech for ZILRETTA.
- Announced an exclusive license agreement with AmacaThera for AMT-143 (ropivacaine formulation).
- Continued share repurchases under a $300M program authorized in April 2025; approximately $200M remains available.
- Risks & Contingencies:
- Generic Competition: Received Paragraph IV certifications from two Chinese manufacturers (WhiteOak and Qilu) challenging EXPAREL patents in October 2025. The company intends to litigate.
- Regulatory: Ongoing pediatric trial commitments for EXPAREL with the FDA and EMA.
- Macroeconomic: Potential impact of tariffs on pharmaceutical imports and the ongoing U.S. government shutdown affecting FDA operations.
Investor Verification Checklist
- Patent Litigation Status: Verify the timeline and potential impact of the new Paragraph IV challenges from WhiteOak and Qilu on EXPAREL exclusivity.
- PCRX-201 Clinical Data: Monitor upcoming interim results from the Phase 2 ASCEND trial for knee OA, a key growth driver.
- Debt Covenants: Review compliance with the new Revolving Credit Facility covenants, specifically the Senior Secured Net Leverage Ratio.
- Manufacturing Efficiency: Assess the realized cost savings from the decommissioning of the 45-liter EXPAREL suite and the transition to 200-liter suites.
- Contingent Consideration: Track the fair value adjustments of the Flexion Acquisition contingent consideration, which fluctuates based on discount rates and sales forecasts.